Call for Abstracts
Abstract submission deadline
3:00pm, September 24, 2020 (Japan Standard Time, UTC+9)
Extended to 3:00pm, September 30, 2020 (Japan Standard Time, UTC+9)
Extended to 3:00pm, October 5, 2020 (Japan Standard Time, UTC+9)
Call for Abstracts is now closed.
Abstract submission guidelines
- 1. All applicants are required to create a user account first. After creating the account, you can submit your abstract for this annual meeting with the account.
- 2. Once the submission is completed, a confirmation e-mail will be sent automatically. If you do not receive the confirmation e-mail within 24 hours after submission, please contact the Conference Secretariat (jshct2021@jtbcom.co.jp).
- 3. Abstract number will be generated automatically when an abstract is submitted.
- 4. For changes, withdrawal or additional submission, please log in to the system using your ID and password from "Abstract Submission" button at the bottom of this page.
Application for general presentation (Oral/Poster)
1. SELECT THE DESIRED STYLE OF YOUR PRESENTATION
Submitted abstracts will be assigned for Oral presentation or Poster presentation depending on the results of peer review.
ORAL PRESENTATION:
PC presentation only (film slides or videotapes are not allowed)
POSTER PRESENTATION:
Discussion in the Poster
2. SELECT AN APPROPRIATE CATEGORY FROM THE FOLLOWING LIST
Main Category |
Sub Category |
01. Stem Cell Biology |
|
02. Histocompatibility Antigen |
|
03. Stem Cell Mobilization and Harvest |
|
04. Stem Cell Source |
|
05. Conditioning Regimens |
|
06. Supportive Care |
|
07. Transplant Immunity |
07-1. Immune Reconstitution |
07-2. Acute GVHD |
07-3. Chronic GVHD |
07-4. GVL |
07-5. Others |
08. Immunotherapy/Cell Therapy |
|
09. Child-specific Transplant Disease
(Inborn errors of metabolism,
Congenital immune deficiency and others) |
|
10. Transplant Outcomes |
10-1. Acute Leukemia |
10-2. Myelodysplastic Syndrome/
Myeloproliferative Tumor |
10-3. Malignant Lymphoma/ATL |
10-4. Multiple Myeloma/Plasma Cell Disorders |
10-5. Aplastic Anemia |
10-6. Others |
11. Minimal Residual Disease and Relapse |
|
12. Early Complications |
12-1. Engraftment Failure |
12-2. TMA |
12-3. VOD/SOS |
12-4. Others |
13. Late Complications |
|
14. Infection |
14-1. Bacterial Infection |
14-2. Fungal Infection |
14-3. Viral Infection |
14-4. Others |
15. Follow-up and QOL |
|
16. Marrow Donor Program/
Cord Blood Bank/Donors |
|
17. Hematopoietic Cell Transplant Coordinator
and Coordinate |
|
18. Care |
18-1. Oral Care |
18-2. Skin Care |
18-3. GVHD Care |
18-4. Mental Care |
18-5. Others |
19. Management |
19-1. Infection Control |
19-2. Meal Management |
19-3. Nutrition Management |
19-4. Others |
20. Rehabilitation |
|
21. Nursing/Education |
|
22. TDM/Drugs |
|
23. Team Medical-care |
|
Guidelines for abstract preparation
- 1. The title should be no longer than 100 characters including spaces. Affiliation(s) should be written concisely and the abstract no longer than 1800 characters including spaces. In case you need to add an image (picture, chart or diagram) in your abstract, the word limitation will be reduced to 900 characters.
- 2. The abstract should be arranged under the following headings: Objective, Subjects and Methods, Results, Conclusions. For case reports and invention or improvement of techniques and devices, the headings should be appropriately changed (for example, for case reports, Introduction, Cases, Discussion and if relevant, Conclusions).
- 3. Presentations, abstracts and presentation data must be prepared in English.
- 4. See below for declaration of conflict of interests.
- 5. On abstract submission form, please select whether you have obtained an approval of the ethics committee, e.g. IRB, or if it is not necessary. This does not need to be stated in the abstract text.
Conflict of interest
- 1. When you submit an abstract, please report whether there are potential conflicts of interest with companies concerned with the content of your presentation within the last three years.
- 2. The authors (include co-authors) are required to disclose applicable COI by displaying a COI disclosure slide at the beginning of presentation slides (the slide after the title of presentation and the name of presenters) or at the end of a poster using samples as attached.
Personal information protection
"Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the "presenters' names," "affiliation names," "title" and "abstract text" shall be used for publication in the program/abstract book and on the website, but not for other purposes. The registration process for applications has been commissioned to the Conference Secretariat c/o JTB Communication Design, Inc. in order to facilitate management operations